Daigle, Denis Marc
- Venatorx Pharmaceuticals, Inc. (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #5,355
- R01 Holder
- Early Career
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2019 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$1.6M
Full award amounts, FY2023
Award Records
1
Records listing this PI
Award-Linked Rank
#5,355
By linked amount among FY2023 PIs
Earliest Year Loaded
2019
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Daigle, Denis Marc as a PI. Multi-PI records show the full award amount for context.
- 5R01AI141239-05R01Contact PINew class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae$1.6Maward amount
Award organization
Organizations that administered FY2023 awards listing Daigle, Denis Marc as a PI.
FY2023 award administered by Venatorx Pharmaceuticals, Inc. (PA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2019First NIH AwardVenatorx Pharmaceuticals, Inc.
- 2019$500K Cumulative Funding
- 2019$1M Cumulative Funding
- 2019Entered Top 50% NationallyRanked #4829
- 2019Entered Top 25% NationallyRanked #4829
- 2021$2M Cumulative Funding
- 2021R01 Grant Holder
- 2023$5M Cumulative Funding